International Journal of Research in Engineering and Science (IJRES)
ISSN (Online): 2320-9364, ISSN (Print): 2320-9356
www.ijres.org Volume 10 Issue 1 ǁ 2022 ǁ PP. 40-45

S100B A Cause and Consequence Relationship in Alzheimer Disease

Yousef .Sawikr[*1]
Department of Pharmacology and Toxicology, Faculty of Medicine University of Ajdabiya, Libya.
Faraj A. Alsarrah* [2]
Department of Dermatology, Faculty of Medicine University of Ajdabiya, Libya.
Samir Elmrghni*[3]
Department of Forensic Medicine and Toxicology, Faculty of Medicine, University of Benghazi-Libya
Khlid G ALqathafy*[4]
Department of Biochemistry, Faculty of Medicine, University of Benghazi, Libya.
Corresponding Author: Yousef .Sawikr (PhD)

Abstract:
*S100B is a 21-kDa calcium-binding protein of the EFhand type(helix E-loop-helix F) mainly expressed and constitutively released astrocytes and Present primarily in the nervous system, and has different (trophies, toxic) effects on neurons, astrocytes, microglia depend on the concentration**.** Affects the survival and differentiation of both neurons and glia cells. Elevated levels of S100β protein have been observed in the brains of individuals with Alzheimer Disease (AD), as well as in those with Down Syndrome (DS)**.** overexpression of s100B accelerates Alzheimer disease like pathology with enhanced astrogliosis and microgliosis**.** Increased the neurotrophic signaling molecule S100B has been detected with various clinical conditions. Brain trauma and ischemia is associated with increased S100B concentrations, probably due to the destruction of astrocytes**.** Pivotal role has emerged for S100B as an important contributor in Alzheimer disease pathology **,**as S100B appears to modulate several neuropathologyical mechanism in Alzheimer disease .evidence for the involvement of S100B in Alzheimer disease pathology and neuronal loss come from studies S100B overexpression ,S100B localization studies , multiple relationship between S100B and increase amyloid precursore protein interaction between S100B and dystrophic neuritcs plaques and neurofibrillary tangle change in Alzheimer disease this review focuses on the significance of S100B in brain damage and degenerative brain disease* **.**
Keywords *Alzheimer disease , S100B ,cytokines, RAGE,*

Date of Submission: 27-12-2021 Date of acceptance: 06-01-2022

I. INTRODUCTION :

Alzheimer's disease (AD) is a chronic, progressive loss of basal forebrain cholinergic neurons , and irreversible neurodegenerative disease with clinical characteristics of memory loss, dementia and impairment in memory, visuospatial skills, complex cognition, language, emotion and personality. Prominent neuropathologic features of AD are senile plaques, neurofibrillary lesions, synaptic and neuronal loss, and gliosis ,destroys the higher structures of the brain. The formation of amyloid plaques and neurofibrillary lesions are thought to contribute to the neurodegeneration in the brain of Alzheimer's disease sufferers play an important role in the inflammatory response in the CNS and in AD pathogenesis. cognitive dysfunction concomitant with the accumulation of senile plaques (SP) is consist of Beta-amyloid (Aβ) plaques (extracellular Aβ deposition) and neurofibrillary tangles (NFT, intracellular deposits of hyper-phosphorylated tau protein) have been identified as two classical pathological hallmarks of AD. Accordingly, numerous studies have focused on Aβ generation and deposition as well as on NFT formation as the triggering factors for AD occurrence . Gliosis is also seen in AD: activated astrocytes and microglia are characteristically found in abundance near neurons and plaques, and this can be seen even in a case described by Alzheimer in1911.This suggests that inflammation maybe involved in AD, because glial cells mediate the innate immune response in the central nervous system. When activated, astrocytes and microglia produce several proinflammatory signal molecules, including cytokines, growth factors, complement molecules, and adhesion molecules. Of particular interest in AD are the cytokines S100B , which is mainly produced by astrocytes, and interleukin1(IL-1),which is mainly produced by activated microglia



Figure S100B

Role of Astrocytes in Alzheimer's Disease:

Histo pathological features of AD include large extracellular senile plaques (SPs) composed of the amyloid-β (Aβ) plagues and neurofibrillary tangles, which [1]are intra cellular inclusions of hyperphosphorylated tau protein in selective regions of the brain (Koistinaho et al. 2004; Nagele et al.2003)[2].[1] β -amyloid is a peptide of 42 amino acid residues produced by the selective photolytic cleavage of transme brane amyloid precursor proteins (APP) by β and γsecretases (Haassand Selkoe 1993). Aβ can directly induce [3]neuronal cytotoxicity,but the relevance of such toxicity to the disease is controversial(Pimplikar 2009; Yankner, Duffy, and Kirschner 1990[1]).Morphological characterization of GFAP-positive astroglial cells performed on AD mouse model at different ages showed an age-dependent reduction in GFAP expression (Rodrı´guezet al. 2009). These authors suggested that in an AD transgenic, reactive hypertrophic astrocytes surround the neuritic plaques whereas astroglial cells in other brain regions undergo atrophy, which may account for early changes in synaptic plasticity and cognitive impairments inherent to AD. In the AD human tissue ,prominent astrogliosis occurs in the cells surrounding amyloid plaques, and these activated astrocytes accumulate large amounts of Ab42, which are derived from neuronal debris and associated with plaques (Nagele et al. 2003)[4]. Moreover ,astrocytes from patients with dementia show significantly decreased complexity compared to the healthy brain(Senitz,Reichenbach, and Smith 1995).[3] It is widely recognized that age is the most important risk factor for AD and that the innate immune system plays a role in the development of neurodegeneration. Very little information is available on how aging affects the innate immune system. However, there are clear indications that the development of AD is due to age-related changes that modulate innate immunity. It is interesting that Aβ and other proteins found in the senile plaques of AD patients are potent activators of the innate immune response because chronic stimulation of the innate immune system may lead to alterations of astrocytes. When the brain is injured, astrocytes are believed to react by putting down glial scar tissue as part of the healing process. Recently, it has been shown that astrocytes themselves actively contribute to the inflammatory response ([5]Farina, Aloisi et al. 2007). It has been shown that the neurotransmitter glutamate is released in neuroinflammatory conditions and to some degree under normal circumstances, which on the long term is proved to be toxic to neurons. The neuroprotective action of astrocytes has also been attributed to their capacity to take up the neurotransmitter glutamate, convert it to glutamine, and recycle it to neurons [6].

Neuroinflammation and immune system crosstalk in Alzheimer disease:

Neuroinflammation is the mechanism of CNS inflammation that occurs in response to trauma, infections, and/ or neurodegenerative diseases. In neuroinflammation, cellular and molecular immune components such as specialised macrophages (microglia), cytokines,chemokines complement, tumor necrosis factor(TNF). [7]recruited from the peripheral system following disruption of the blood-brain barrier. Alterations in the permeability of the BBB and chemotaxis may permit the recruitment and passage of peripheral cells into the brain parenchyma. Determining the detailed mechanism of this process is an active area of research. Investigators are exploring the processes involved in both the passage of inflammation into, and the effect of cytokines on, the central nervous system (CNS)[8] This in turn leads to the activation of the glial cells, such as microglia and astrocytes. The effect of neuroinflammation is considered neuroprotective when the inflammatory

activity is for a shorter period of time whereas chronic neuroinflammation is associated with harmful consequences for the CNS. [7][9] In the brain, inflammation is mediated largely by glial cells, the support cells of the nervous system. Glial cells include astrocytes, which support neuronal metabolism, oligodendrocytes which produce myelin insulation for nerve cells (allowing more efficient conduction of nerve impulses), and microglia, which serve as a kind of immune system. Glial cell activation is a key feature of brain inflammation. When activated, microglia produce inflammatory mediators that activate more cells to produce additional inflammatory mediators. These mediators can thus create positive feedback loops, thereby amplifying inflammation. Brain inflammation, including increased microglia and astrocyte [10] activation, generally increases as part of the aging process and brain inflammation is a key feature of neurodegenerative diseases, including AD . The immune system comprises a complex interrelated network of cellular, molecular, and chemical mediators that function to protect the body against environmental stress factors. These stressors can be as diverse as microorganisms (viral, bacterial, fungal agents), physical damage (burns, lacerations), or environmental toxins (snake venoms, nonessential metals, chemicals). To combat all these stressors, the first line of defense is innate or natural immunity. The inflammatory component of this response is important in recruiting cells of the immune system to the compromised area, and cytokines and chemokines mediate this function. Cytokines orchestrate a specific response that is appropriate based on the type of foreign antigen that has penetrated the tissue, and chemokines are important in allowing cells of the immune system to reach the area under attack[11]some endogenous factor are response by inhibition proinflammatory gene expression via negative feed back inhibition [12]however over activation of innate immunity can lead to neurodegenerative disorders which is accompaniedby enhanced expression level of S100B and S100B receptor ,RAGE in neural and inflammatory and cytokines and chemokines e.g TNF ,IL-1,S100B. have been implicated as etiological factors in a variety of neurological disease states including AD[13]



Figure: Neuroinflammation and immune system in Alzheimer disease

RELATION BETWEEN S100B, INTERLEUKIN 1, AND ALZHEIMER DISEASE:
S100B IN ALZHEIMER DISEASE:

S-100B proteins, named for their solubility in a 100% saturated solution of ammonium sulphate at neutral pH[14]. It is belong to a group of closely related, small, acidic, water-soluble, Ca^{2+} -binding proteins[15][16] . A great body of evidence suggests that S-100 could be viewed as a multifunctional subfamily of Ca2+-binding proteins of the EF-hand type. A large number of diverse functions is attributed to S-100 proteins, ranging from calcium-buffering through intracellular (e.g., modulation of enzyme activities, energy metabolism, motility, and secretion cell proliferation and differentiation, cytoskeletal assembly and disassembly) and nuclear (e.g., transcription and apoptosis) functions to extracellular activities (e.g., secretion, neurite extension, calcium homeostasis and chemotaxis)[17] S100B, one of the originally described S100 proteins, is abundantly expressed by central and peripheral nervous system glia, and to a much lesser extent, by some populations of neurons[18][19] S100B is detected in varying abundance in a limited number of brain cells

including astrocytes, maturing oligodendrocytes, neuronal progenitor cells, pituicytes, ependymocytes, and certain neural populations. Although the majority of astrocytic S100B localizes within the cytoplasm, 5%–7% is membrane bound. S100B is also expressed by non-neural cells, including melanocytes, chondrocytes, and adipocyte[17]increased S100B levels are also found in the cerebral spinal fluid of A.D patients[20] Astrocytic S100B is considered to be the major factor contributing to the formation of dystrophic neurites, which are pathologically transformed neurites concentrated around amyloid plaques [21] [22] AD neuropathological hallmarks include brain deposition of amyloid-β (Aβ) peptide as senile plaques, accumulation of abnormal tau protein filaments as intracellular neurofibrillary tangles, extensive neuronal degeneration and loss, profound synaptic loss, and β-amyloid plaque associated astrocytosis and microgliosis[23][24] S100B release is driven by the developmental stage of the astrocytes [25]and metabolic stress (oxygen, serum, or glucose deprivation)[26] S100B can also be released in response to external stimuli such as glutamate[27], serotonin [28] ,the pro-inflammatory cytokines TNF-alpha [29] and IL-1beta [30], beta-amyloid peptides[31] ,1-methyl- 4-phenyl 1,2,3, and 6 tetrahydropyridine (MPTP) [32], forskolin, lysophosphatidic acid[33] .Local synaptic responses with local overexpression of the Aβ precursor protein and local astrocyte activation with over expression of S100B might then be responsible in part for the progression of pathology across brain regions in Alzheimer's disease.

Interleukin-1:

Interleukin-1 was first described in 1972 as a lymphocyte activating factor[34] and later was shown to exert a variety of effects including induction of inflammation, body temperature increase, proliferation of T and B cells, induction of acute phase proteins and prostaglandins and regulation of hematopoesis. Its activities are not restricted to the immune system. Interleukin-1 is also involved in the regulation of blood calcium levels, stimulation of proliferation of various cells, regulation of blood pressure or modulation of sleep. However, IL-1 represents one of the most important mediators of the inflammatory response that induces a cascade of proinflammatory effector molecules.[35]) Interleukin-1 (IL-1) has been implicated in a number of neurodegenerative conditions and is generally believed to have neurotoxic actions, although the mechanisms of these effects are unclear (Lucas et al, 2006[36]. There are two molecular forms (ILla and IL- IB), that is secreted by microglia and astrocytes. IL- 1 produced by activated microglia may trigger production of other cytokines, such as IL-6, TNF-a by astrocytes and other cells.

Furthermore, IL-1 induces astrocytes and neurons to produce more B-amyloid which leads to deposition of amyloid fibrils (Griffin et al, 1995, Nilsson et al, 1998)[36]. Through various pathways, IL- 1 causes neuronal death, which activates more micrglia, which in tum releases more IL-1 in a self-sustaining and self-amplifying fashion. Interleukin-6 (IL-6) is a multifunctional cytokine that stimulates the acute-phase reaction, which enhances the innate immune system and protects against tissue damage. IL-6 is synthetised by microglia, astrocytes, neuronal and endothelial cells. In certain condition, IL-6 may have inflammatory or immunosuppressive effects (Ferencik et al, 200 1).[37] IL-6 seems to act as a secondary process amplifying the inflammatory response initiatedby IL- IB (Lee et al, 1993)[38]. Elevated levels of IL-6 mRNA were demonstrated in the entorhinal cortex and the superior temporal gyrus of AD patients (Ge and Lahiri, 2002, Lahiri et al, 2003)[39] IL-1 is markedly overexpressed by activated microglia in Alzheimer's disease [40] and, like activated astrocytes, these activated microglia show characteristic patterns of association with different stages of A neuritic plaques. and enhances production and processing of (β-amyloid precursor protein (β-APP). A major inducer of astrocyte activation and S100B expression is the immunomodulatory cytokine IL-1 [41][42]Activated Microglia overexpressing IL-1, like activated astrocytes overexpressing S100B, are frequently found in the early nonfibrillar amyloid deposits of Alzheimer's disease[43][44]. These proposed pathogenic mechanisms elevated levels of the inflammatory cytokine IL-1 drive S100β and β-APP overexpression and dystrophic neurite formation in Alzheimer's disease. interact with other cellular and molecular factors to form a cytokine cycle of molecular cascades with feedback amplification of glial activation and with progressive neuronal injury[45][46] . In moreover to the previously mentioned, S100B-mediated effects on free calcium levels and on dystrophic neurite formation within neuritic A plaques, there are other consequences of cytokine cycle activation. IL-1 expression.[47] Astrocytic S100β, in turn, i) increases intracellular free calcium concentrations, ii) promotes growth of neuronal processes that, coincidentally, necessitate further neuronal expression ofβ-APR favoring release of neurotoxic β-amyloid; and iii) induces astrocytic nitric oxide synthase activity with release of potentially neurotoxic nitric oxide. The resultant neuronal cell dysfunction and death, together with β-amyloid activation of the classical complement pathway microglial IL-1 overexpression i) promotes astrocyte activation and upregulates astrocytic expression of S100β, ApoE, α1-antichymotrypsin and the complement protein C3; ii) stimulates neuronal synthesis and processing ofβ-APP; and iii) has autocrine effects to activate microglia and to further promote IL-1 expression[48]

RAGE in Alzheimer disease :

non-enzymatic glycosylation theory of aging' proposed that the AGE-mediated crosslinking of long-lived proteins contributes to the age-related decline in the function of cells and tissues in normal aging[49] , AGEs and S100B are also abundant in the nervous system, therefore their interaction with RAGE appears to be implicated not only to the pathology of amyloid-type disorders, but with other neurodegenerative disorders such as Huntington's disease (HD) Parkinson's disease (PD) and amyotrophiclateral sclerosis (ALS) [50] RAGE expression, apart from neurons, microglial cells astrocytes in the healthy human brain[51] The involvement of AGEs in brain aging and – in an accelerated fashion – in AD was first proposed in the mid 1990s[52] The stability of proteins that constitute the long-lived intracellular (neurofibrillary tangles and Hirano Bodies) and extracellularn protein deposits (senile plaques) suggests that they would be ideal substrates for glycation, a process that occurs over a long time, even at normal levels of glucose, ultimately resulting in the formation of AGEs. establishing a link between the expression of RAGE and the pathophysiological changes in AD, showed that extracellular deposition of Aβ and its interaction with the brain vasculature or directly with neurons and microglia, lead to neuronaldysfunction. The latter dysfunction was mediated by RAGE in a dose dependent manner and moreover, binding of Aβ to RAGE generated oxidative stress, activation of NF-kB and induced expression of macrophage-colony stimulating factor (M-CSF).[53] AGE harmless post-translational protein modification; various pathophysiological effects have been found at the cellular and molecular level. One of the proposed mechanisms of AGE-induced damage are reactive oxygen species (ROS), particularly superoxide and hydrogen peroxide released by AGEs[54] The activation of microglial RAGE by many of its ligands, including AGEs andAβ, results in the release of proinflammatory mediators such as free radicals and cytokines[55] Additionally, in astrocytes of AD brain, epitopes of Aβ, AGEs and RAGE were found to co-localize, suggesting a potential participation in the pathogenesis of the disease[56] microglia had increased expression levels of IL-1 and TNF-α, suggesting an inverse correlation between cytokine production and Aβ clearance. These data indicate that, although early microglial recruitment promotes Aβclearance and is neuroprotective in AD, as the disease progresses, proinflammatory cytokines are produced in response to Aβdeposition (with RAGE as the A β-binding receptor), which then downregulate genes involved in A β clearance and promote Aβ accumulation. Microglia may thus contribute to plaque formation, accumulation of AGEs on plaques over time, more intense crosslinking, inflammation and chronic neurodegeneration. As S100 proteins and especially S100B are abundantly expressed in the nervous system, Huttunen and his coworkers initially suggested that RAGE, already known to interact with Aβ, can also mediate neurotoxicity due to elevated levels of S100B, shedding new light on studies of the molecular pathophysiology of AD [14]. S100B stimulated NF-kB transcriptional activity in microglia in a manner that was strictly dependent on RAGE, therefore pointing to additional RAGE-mediated effects on microglia activation withimpact in AD and other neurodegenerative disorders. [57].

II. Conclusion and perspective:

Astrocytes play a critical role in normal function of the mammalian nervous system Astrocytes And a significant role in neurodegenerative diseases and coordinates many of the initial and subsequent responses of astrocytes to injury Astroglial cells are specifically involved in various neurological diseases, Astrocytes regulate synaptic transmission and plasticity, protect neurons against toxic compounds, and support metabolically to ensure their optimal functioning. , they support neurons. By providing growth factors and cytokines chemokines and IL-1α Astrocytes are involved in all types of neurodegenerative processes, and display prominent remodelling in the AD; early dystrophic changes in astroglia can represent an important step in initiation and progression of Alzheimer's disease. Targeting of astroglia may provide a new principle for treatment of AD at the early stages of the disease.

REFERENCES

[1] T. Wyss-Coray and J. Rogers, "Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature.," *Cold Spring Harb. Perspect. Med.*, vol. 2, no. 1, p. a006346, Jan. 2012.

[2] Q. Xiao, P. Yan, X. Ma, H. Liu, R. Perez, A. Zhu, E. Gonzales, J. M. Burchett, D. R. Schuler, J. R. Cirrito, A. Diwan, and J.-M. Lee, "Enhancing Astrocytic Lysosome Biogenesis Facilitates A Clearance and Attenuates Amyloid Plaque Pathogenesis," *J. Neurosci.*, vol. 34, no. 29, pp. 9607–9620, Jul. 2014.

[3] M. Sidoryk-Wegrzynowicz, M. Wegrzynowicz, E. Lee, A. B. Bowman, and M. Aschner, "Role of astrocytes in brain function and disease.," *Toxicol. Pathol.*, vol. 39, no. 1, pp. 115–23, Jan. 2011.

[4] M. R. D'Andrea, G. M. Cole, and M. D. Ard, "The microglial phagocytic role with specific plaque types in the Alzheimer disease brain.," *Neurobiol. Aging*, vol. 25, no. 5, pp. 675–83, 2004.

[5] M. Sidoryk-Wegrzynowicz and M. Aschner, "Role of astrocytes in manganese mediated neurotoxicity.," *BMC Pharmacol. Toxicol.*, vol. 14, p. 23, Jan. 2013.

[6] S. Vesce, D. Rossi, L. Brambilla, and A. Volterra, "Glutamate release from astrocytes in physiological conditions and in neurodegenerative disorders characterized by neuroinflammation," *Int. Rev.* ..., 2007.

[7] K. M. Murphy, *Janeway's Immunobiology*. .

[8] A. Fung, M. Vizcaychipi, D. Lloyd, Y. Wan, and D. Ma, "Central nervous system inflammation in disease related conditions: mechanistic prospects.," *Brain Res.*, vol. 1446, pp. 144–55, Mar. 2012.

[9] L. M. Boulanger, G. S. Huh, and C. J. Shatz, "Neuronal plasticity and cellular immunity: shared molecular mechanisms.," *Curr. Opin. Neurobiol.*, vol. 11, no. 5, pp. 568–78, Oct. 2001.

[10] J. A. Joseph, B. Shukitt-Hale, G. Casadesus, and D. Fisher, "Oxidative stress and inflammation in brain aging: nutritional considerations.," *Neurochem. Res.*, vol. 30, no. 6–7, pp. 927–35, Jan. .

[11] A. Campbell, "Inflammation, neurodegenerative diseases, and environmental exposures.," *Ann. N. Y. Acad. Sci.*, vol. 1035, pp. 117–32, Dec. 2004.

[12] S. Nadeau and S. Rivest, "Glucocorticoids play a fundamental role in protecting the brain during innate immune response," *J. Neurosci. 2003.*

[13] M. Huell, S. Strauss, B. Volk, M. Berger, and J. Bauer, "Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients," *Acta Neuropathol.*, vol. 89, no. 6, pp. 544–551, 1995.

[14] C. J. Sindic, M. P. Chalon, C. L. Cambiaso, E. C. Laterre, and P. L. Masson, "Assessment of damage to the central nervous system by determination of S-100 protein in the cerebrospinal fluid.," *J. Neurol. Neurosurg. Psychiatry*, vol. 45, no. 12, pp. 1130–1135, Dec. 1982.

[15] M. Mata, D. Alessi, and D. J. Fink, "S100 is preferentially distributed in myelin-forming Schwann cells," *J. Neurocytol.*, vol. 19, no. 3, pp. 432–442, Jun. 1990.

[16] D. B. Zimmer, E. H. Cornwall, A. Landar, and W. Song, "The S100 protein family: History, function, and expression," *Brain Res. Bull.*, vol. 37, no. 4, pp. 417–429, Jan. 1995.

[17] R. Donato, "Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type," *Biochim. Biophys. Acta - Mol. Cell Res.*, vol. 1450, no. 3, pp. 191–231, Jul. 1999.

[18] H. Ichikawa, D. Jacobowitz, and T. Sugimoto, "S100 protein-immunoreactive primary sensory neurons in the trigeminal and dorsal root ganglia of the rat," *Brain Res. 1997.*

[19] Q. Yang, A. Hamberger, H. Hyden, S. Wang, T. Stigbrand, and K. G. Haglid, "S-100β has a neuronal localisation in the rat hindbrain revealed by an antigen retrieval method," *Brain Res.*, vol. 696, no. 1–2, pp. 49–61, Oct. 1995.

[20] E. R. Peskind, W. S. T. Griffin, K. T. Akama, M. A. Raskind, and L. J. Van Eldik, "Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease," *Neurochem. Int.*, vol. 39, no. 5–6, pp. 409–413, Nov. 2001.

[21] R. E. Mrak and W. S. T. Griffin, "Glia and their cytokines in progression of neurodegeneration.," *Neurobiol. Aging*, vol. 26, no. 3, pp. 349–54, Mar. 2005.

[22] N. J. Cairns, A. Chadwick, P. J. Luthert, and P. L. Lantos, "Astrocytosis, βA4-protein deposition and paired helical filament formation in Alzheimer's disease," *J. Neurol. Sci.*, vol. 112, no. 1–2, pp. 68–75, Oct. 1992.

[23] X. Zhang and W. Song, "The role of APP and BACE1 trafficking in APP processing and amyloid-β generation.," *Alzheimers. Res. Ther.*, vol. 5, no. 5, p. 46, Jan. 2013.

[24] D. J. Selkoe, "Alzheimer's disease: genes, proteins, and therapy.," *Physiol. Rev.*, vol. 81, no. 2, pp. 741–66, Apr. 2001.

[25] L. J. Van Eldik and D. B. Zimmer, "Secretion of S-100 from rat C6 glioma cells," *Brain Res.*, vol. 436, no. 2, pp. 367–370, Dec. 1987.

[26] "Active secretion of S100B from astrocytes during metabolic stress.," *Neuroscience*, vol. 141, no. 4, pp. 1697–701, Sep. 2006.

[27] "Unbound MEDLINE : Activation of A(1) adenosine or mGlu3 metabotropic glutamate receptors enhances the release of nerve growth factor and S-100beta protein from cultured astrocyte." [Online]. Available: http://www.unboundmedicine.com/medline/citation/10457374/Activation_of_A_1__adenosine_or_mGlu3_metabotropic_glutamate_receptors_enhances_the_release_of_nerve_growth_factor_and_S_100beta_protein_from_cultured_astrocytes_. [Accessed: 18-Feb-2015].

[28] P. M. Whitaker-Azmitia, R. Murphy, and E. C. Azmitia, "Stimulation of astroglial 5-HT1A receptors releases the serotonergic growth factor, protein S-100, and alters astroglial morphology.," *Brain Res.*, vol. 528, no. 1, pp. 155–8, Sep. 1990.

[29] M. M. Edwards and S. R. Robinson, "TNF alpha affects the expression of GFAP and S100B: implications for Alzheimer's disease.," *J. Neural Transm.*, vol. 113, no. 11, pp. 1709–15, Nov. 2006.

[30] D. F. de Souza, M. C. Leite, A. Quincozes-Santos, P. Nardin, L. S. Tortorelli, M. M. Rigo, C. Gottfried, R. B. Leal, and C.-A. Gonçalves, "S100B secretion is stimulated by IL-1beta in glial cultures and hippocampal slices of rats: Likely involvement of MAPK pathway.," *J. Neuroimmunol.*, vol. 206, no. 1–2, pp. 52–7, Jan. 2009.

[31] L. Peña, C. Brecher, and D. Marshak, "β-amyloid regulates gene expression of glial trophic substance S100β in C6 glioma and primary astrocyte cultures," *Mol. brain Res. 1995.*

[32] T. Iuvone, G. Esposito, D. De Filippis, T. Bisogno, S. Petrosino, C. Scuderi, V. Di Marzo, and L. Steardo, "Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro.," *J. Mol. Med. (Berl).*, vol. 85, no. 12, pp. 1379–92, Dec. 2007.

[33] S. S. Pinto, C. Gottfried, A. Mendez, D. Gonçalves, J. Karl, C. A. Gonçalves, S. Wofchuk, and R. Rodnight, "Immunocontent and secretion of S100B in astrocyte cultures from different brain regions in relation to morphology.," *FEBS Lett.*, vol. 486, no. 3, pp. 203–7, Dec. 2000.

[34] I. Gery and B. H. Waksman, "Potentiation of the T-lymphocyte response to mitogens II. The cellular source of potentiating mediator (s)," *J. Exp. Med.*, vol. 136, no. 1, pp. 143–155, 1972.

[35] V. Sharma, "Neuroinflammation in Alzheimer's disease and Involvement of Interleukin-1: A Mechanistic View," *Int. J. Pharm. Sci. ...*, 2011.

[36] N. Zilka, M. Ferencik, and I. Hulin, "Neuroinflammation in Alzheimer □ s disease : protector or promoter ?," vol. 107, no. 2, pp. 374–383, 2006.

[37] A. Klegeris and P. McGeer, "Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Other Anti- Inflammatory Agents in the Treatment of Neurodegenerative Disease," *Curr. Alzheimer Res.*, vol. 2, no. 3, pp. 355–365, Jul. 2005.

[38] S. C. Lee, W. Liu, D. W. Dickson, C. F. Brosnan, and J. W. Berman, "Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1 beta.," *J. Immunol.*, vol. 150, no. 7, pp. 2659–67, Apr. 1993.

[39] Y.-W. GE and D. K. LAHIRI, "Regulation of Promoter Activity of the APP Gene by Cytokines and Growth Factors," *Ann. N. Y. Acad. Sci.*, vol. 973, no. 1, pp. 463–467, Nov. 2002.

[40] S. S. Shaftel, W. S. T. Griffin, and M. K. O'Banion, "The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective.," *J. Neuroinflammation*, vol. 5, p. 7, Jan. 2008.

[41] D. Giulian, J. Woodward, D. G. Young, J. F. Krebs, and L. B. Lachman, "Interleukin-1 injected into mammalian brain stimulates astrogliosis and neovascularization.," *J. Neurosci.*, vol. 8, no. 7, pp. 2485–90, Jul. 1988.

[42] J. G. Sheng, K. Ito, R. D. Skinner, R. E. Mrak, C. R. Rovnaghi, L. J. Van Eldik, and W. S. Griffin, "In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis.," *Neurobiol. Aging*, vol. 17, no. 5, pp. 761–6, Jan. .

[43] W. S. Griffin, J. G. Sheng, G. W. Roberts, and R. E. Mrak, "Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution.," *J. Neuropathol. Exp. Neurol.*, vol. 54, no. 2, pp. 276–81, Mar. 1995.

[44] I. R. A. Mackenzie, C. Hao, and D. G. Munoz, "Role of microglia in senile plaque formation," *Neurobiol. Aging*, vol. 16, no. 5, pp. 797–804, Sep. 1995.
[45] W. S. T. Griffin and R. E. Mrak, "Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease.," *J. Leukoc. Biol.*, vol. 72, no. 2, pp. 233–8, Aug. 2002.
[46] R. E. Mrak and W. S. Griffin, "Interleukin-1 and the immunogenetics of Alzheimer disease.," *J. Neuropathol. Exp. Neurol.*, vol. 59, no. 6, pp. 471–6, Jun. 2000.
[47] R. Mrak, "The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer's disease," *Neurobiol. Aging*, vol. 22, no. 6, pp. 915–922, Dec. 2001.
[48] J. Hu and L. J. Van Eldik, "Glial-derived proteins activate cultured astrocytes and enhance beta amyloid-induced glial activation," *Brain Res.*, vol. 842, no. 1, pp. 46–54, Sep. 1999.
[49] V. Monnier and A. Cerami, "Nonenzymatic browning in vivo: possible process for aging of long-lived proteins," *Science (80-.).*, vol. 211, no. 4481, pp. 491–493, Jan. 1981.
[50] L. Ma and L. F. . Nicholson, "Expression of the receptor for advanced glycation end products in Huntington's disease caudate nucleus," *Brain Res.*, vol. 1018, no. 1, pp. 10–17, Aug. 2004.
[51] J. Brett, A. M. Schmidt, S. D. Yan, Y. S. Zou, E. Weidman, D. Pinsky, R. Nowygrod, M. Neeper, C. Przysiecki, and A. Shaw, "Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues.," *Am. J. Pathol.*, vol. 143, no. 6, pp. 1699–712, Dec. 1993.
[52] S. Takeda, N. Sato, and R. Morishita, "Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy.," *Front. Aging Neurosci.*, vol. 6, p. 171, Jan. 2014.
[53] I. G. Onyango, J. B. Tuttle, and J. P. Bennett, "Altered intracellular signaling and reduced viability of Alzheimer's disease neuronal cybrids is reproduced by beta-amyloid peptide acting through receptor for advanced glycation end products (RAGE).," *Mol. Cell. Neurosci.*, vol. 29, no. 2, pp. 333–43, Jun. 2005.
[54] M. Guglielmotto, L. Giliberto, E. Tamagno, and M. Tabaton, "Oxidative stress mediates the pathogenic effect of different Alzheimer's disease risk factors.," *Front. Aging Neurosci.*, vol. 2, p. 3, Jan. 2010.
[55] B. Schmidt, H. A. Braun, and R. Narlawar, "Drug development and PET-diagnostics for Alzheimer's disease.," *Curr. Med. Chem.*, vol. 12, no. 14, pp. 1677–95, Jan. 2005.
[56] N. Sasaki, S. Toki, H. Chowei, and T. Saito, "Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease," *Brain Res. 2001*.
[57] C. Adami, R. Bianchi, G. Pula, and R. Donato, "S100B-stimulated NO production by BV-2 microglia is independent of RAGE transducing activity but dependent on RAGE extracellular domain.," *Biochim. Biophys. Acta*, vol. 1742, no. 1–3, pp. 169–77, Dec. 2004.